Comment
doi: 10.1056/NEJMc1603180.
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
- PMID: 27332911
- DOI: 10.1056/NEJMc1603180
Item in Clipboard
Comment
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
N Engl J Med.
.
Free article
No abstract available
Comment on
-
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.N Engl J Med. 2016 Feb 11;374(6):511-22. doi: 10.1056/NEJMoa1505533. N Engl J Med. 2016. PMID: 26863353 Clinical Trial.
-
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.N Engl J Med. 2016 Jun 23;374(25):2497. doi: 10.1056/NEJMc1603180. N Engl J Med. 2016. PMID: 27332912 No abstract available.
Similar articles
-
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.N Engl J Med. 2016 Jun 23;374(25):2497. doi: 10.1056/NEJMc1603180. N Engl J Med. 2016. PMID: 27332912 No abstract available.
-
Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura.Am J Health Syst Pharm. 2020 Jul 23;77(15):1201-1207. doi: 10.1093/ajhp/zxaa151. Am J Health Syst Pharm. 2020. PMID: 32588878 Review.
-
Von Willebrand Factor--A New Target for TTP Treatment?N Engl J Med. 2016 Feb 11;374(6):583-5. doi: 10.1056/NEJMe1515876. N Engl J Med. 2016. PMID: 26863360 No abstract available.
-
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.N Engl J Med. 2019 Jan 24;380(4):335-346. doi: 10.1056/NEJMoa1806311. Epub 2019 Jan 9. N Engl J Med. 2019. PMID: 30625070 Clinical Trial.
-
A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura.Expert Rev Hematol. 2020 Nov;13(11):1153-1164. doi: 10.1080/17474086.2020.1819230. Epub 2020 Oct 12. Expert Rev Hematol. 2020. PMID: 32876503 Review.
Cited by
-
Long-term health-related quality of life and mental health in patients with immune thrombotic thrombocytopenic purpura.Ann Hematol. 2024 Jul;103(7):2523-2531. doi: 10.1007/s00277-024-05771-3. Epub 2024 Apr 27. Ann Hematol. 2024. PMID: 38671298 Free PMC article.
-
Plasmic score applicability for the diagnosis of thrombotic microangiopathy associated with ADAMTS13-acquired deficiency in a developing country.Hematol Transfus Cell Ther. 2019 Apr-Jun;41(2):119-124. doi: 10.1016/j.htct.2018.10.002. Epub 2019 Feb 18. Hematol Transfus Cell Ther. 2019. PMID: 31079658 Free PMC article.
-
Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers.Front Immunol. 2017 Dec 8;8:1746. doi: 10.3389/fimmu.2017.01746. eCollection 2017. Front Immunol. 2017. PMID: 29276515 Free PMC article. Review.
-
Outcomes and Costs in Patients with Immune Thrombotic Thrombocytopenic Purpura Receiving Front-Line Versus Delayed Caplacizumab: A US Hospital Database Study.Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241241525. doi: 10.1177/10760296241241525. Clin Appl Thromb Hemost. 2024. PMID: 38523315 Free PMC article.
-
ADAMTS13 or Caplacizumab Reduces the Accumulation of Neutrophil Extracellular Traps and Thrombus in Whole Blood of COVID-19 Patients under Flow.Thromb Haemost. 2024 Aug;124(8):725-738. doi: 10.1055/a-2253-9359. Epub 2024 Jan 25. Thromb Haemost. 2024. PMID: 38272066 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
